The DOI matches its Crossref record; 377 of the 377 references it cites were found in a registry or an index.
Therapeutic cancer vaccines
Open accessAbstract
The clinical benefit of therapeutic cancer vaccines has been established. Whereas regression of lesions was shown for premalignant lesions caused by HPV, clinical benefit in cancer patients was mostly noted as prolonged survival. Suboptimal vaccine design and an immunosuppressive cancer microenvironment are the root causes of the lack of cancer eradication. Effective cancer vaccines deliver concentrated antigen to both HLA class I and II molecules of DCs, promoting both CD4 and CD8 T cell responses. Optimal vaccine platforms include DNA and RNA vaccines and synthetic long peptides. Antigens of choice include mutant sequences, selected cancer testis antigens, and viral antigens. Drugs or physical treatments can mitigate the immunosuppressive cancer microenvironment and include chemotherapeutics, radiation, indoleamine 2,3-dioxygenase (IDO) inhibitors, inhibitors of T cell checkpoints, agonists of selected TNF receptor family members, and inhibitors of undesirable cytokines. The specificity of therapeutic vaccination combined with such immunomodulation offers an attractive avenue for the development of future cancer therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–377 of 377
Yoshitake, Y., Fukuma, D., Yuno, A., Hirayama, M., Nakayama, H., Tanaka, T., Nagata, M., Takamune, Y., Kawahara, K., Nakagawa, Y., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0202 · Cited by 173
Sharma, M., Khong, H., Fa’ak, F., Bentebibel, S.-E., Janssen, L. M. E., Chesson, B. C., Creasy, C. A., Forget, M.-A., Kahn, L. M. S., Pazdrak, B., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14471-1 · Cited by 173
van Deventer, H. W., Burgents, J. E., Wu, Q. P., Woodford, R.-M. T., Brickey, W. J., Allen, I. C., McElvania-Tekippe, E., Serody, J. S., & Ting, J. P.-Y. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1921 · Cited by 172
How Follicular Dendritic Cells Shape the B-Cell Antigenome
Kranich, J., & Kräutler, N. J. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00225 · Cited by 169
van Poelgeest, M. I. E., Welters, M. J. P., Vermeij, R., Stynenbosch, L. F. M., Loof, N. M., Berends-van der Meer, D. M. A., Löwik, M. J. G., Hamming, I. L. E., van Esch, E. M. G., Hellebrekers, B. W. J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2594 · Cited by 167
Self-citationWelters, M. J. P., Ma, W., Santegoets, S. J. A. M., Goedemans, R., Ehsan, I., Jordanova, E. S., van Ham, V. J., van Unen, V., Koning, F., van Egmond, S. I., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2140 · Cited by 167
Self-citationWimmers, F., Schreibelt, G., Sköld, A. E., Figdor, C. G., & de Vries, I. J. M. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00165 · Cited by 166
Targeting T cells to tumor cells using bispecific antibodies
Frankel, S. R., & Baeuerle, P. A. (2013) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2013.03.029 · Cited by 166
Complexity and challenges in defining myeloid-derived suppressor cells
Damuzzo, V., Pinton, L., Desantis, G., Solito, S., Marigo, I., Bronte, V., & Mandruzzato, S. (2015) · Cytometry Part B: Clinical Cytometry · doi:10.1002/cyto.b.21206 · Cited by 165
Cancer associated fibroblast FAK regulates malignant cell metabolism
Demircioglu, F., Wang, J., Candido, J. B., Costa, A. S. H., Casado, P., de Luxán‐Delgado, B., Reynolds, L. E., Gómez-Escudero, J., Newport, E., Rajeeve, V., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15104-3 · Cited by 164
Zumwalt, T. J., Arnold, M., Goel, A., & Boland, C. R. (2014) · Oncotarget · doi:10.18632/oncotarget.3205 · Cited by 163
Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists
Beatty, G. L., Li, Y., & Long, K. B. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1270208 · Cited by 163
Yewdall, A. W., Drutman, S. B., Jinwala, F., Bahjat, K. S., & Bhardwaj, N. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011144 · Cited by 162
Trial watch: dendritic cell vaccination for cancer immunotherapy
Sprooten, J., Ceusters, J., Coosemans, A., Agostinis, P., Vleeschouwer, S. D., Zitvogel, L., Kroemer, G., Galluzzi, L., & Garg, A. D. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1638212 · Cited by 161
Subudhi, S. K., Vence, L., Zhao, H., Blando, J., Yadav, S. S., Xiong, Q., Reuben, A., Aparicio, A., Corn, P. G., Chapin, B. F., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz3577 · Cited by 158
Chemotherapeutic Targeting of Cancer-Induced Immunosuppressive Cells
Alizadeh, D., & Larmonier, N. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0301 · Cited by 158
Fransen, M. F., Sluijter, M., Morreau, H. M., Arens, R., & Melief, C. J. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2888 · Cited by 153
Self-citationAppay, V., Jandus, C., Voelter, V., Reynard, S., Coupland, S. E., Rimoldi, D., Líénard, D., Guillaume, P., Krieg, A. Μ., Cerottini, J., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.3.1670 · Cited by 152
Lopes, J. E., Fisher, J. L., Flick, H. L., Wang, C., Sun, L., Ernstoff, M. S., Alvarez, J. C., & Losey, H. C. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000673 · Cited by 151
Si, Y., Merz, S. F., Jansen, P., Wang, B.-X., Bruderek, K., Altenhoff, P., Mattheis, S., Lang, S., Gunzer, M., Klode, J., et al. (2019) · Science Immunology · doi:10.1126/sciimmunol.aaw9159 · Cited by 150
Xu, D.-Z., Wang, X., Shen, X., Gong, G., Ren, H., Guo, L., Sun, A.-M., Xu, M., Li, L., Guo, X., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.05.003 · Cited by 149
Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial
Kyi, C., Roudko, V., Sabado, R. L., Saenger, Y. M., Loging, W., Mandeli, J., Thin, T. H., Lehrer, D., Donovan, M. J., Posner, M. R., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1866 · Cited by 149
Ascierto, P. A., Kalos, M. D., Schaer, D., Callahan, M. K., & Wolchok, J. D. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2982 · Cited by 147
Zer, A., Sung, M. R., Walia, P., Khoja, L., Maganti, M. D., Labbé, C., Shepherd, F. A., Bradbury, P. A., Feld, R. D., Liu, G., et al. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.04.008 · Cited by 147
Bhardwaj, N., Friedlander, P. A., Pavlick, A. C., Ernstoff, M. S., Gastman, B., Hanks, B. A., Curti, B. D., Albertini, M. R., Luke, J. J., Blazquez, A. B., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00143-y · Cited by 147
Toes, R. E. M., van der Voort, E. I. H., Schoenberger, S. P., Drijfhout, J. W., van Bloois, L., Storm, G., Kast, W. M., Offringa, R., & Melief, C. J. M. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.9.4449 · Cited by 146
Self-citationBhatia, S., Miller, N. J., Lu, H., Longino, N. V., Ibrani, D., Shinohara, M. M., Byrd, D. R., Parvathaneni, U., Kulikauskas, R. M., ter Meulen, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0469 · Cited by 146
Identification of Glycopeptides as Posttranslationally Modified Neoantigens in Leukemia
Malaker, S. A., Penny, S. A., Steadman, L. G., Myers, P. T., Loke, J. C. T., Raghavan, M., Bai, D. L., Shabanowitz, J., Hunt, D. F., & Cobbold, M. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0280 · Cited by 143
Mature neutrophils suppress T cell immunity in ovarian cancer microenvironment
Singel, K. L., Emmons, T. R., Khan, A. N. H., Mayor, P. C., Shen, S., Wong, J. T., Morrell, K., Eng, K. H., Mark, J., Bankert, R. B., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.122311 · Cited by 142
Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer
Gulley, J. L., Madan, R. A., Tsang, K. Y., Jochéms, C., Marté, J. L., Farsaci, B., Tucker, J. A., Hodge, J. W., Liewehr, D. J., Steinberg, S. M., et al. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0108 · Cited by 141
Lawson, D. H., Lee, S., Zhao, F., Tarhini, A. A., Margolin, K. A., Ernstoff, M. S., Atkins, M. B., Cohen, G. I., Whiteside, T. L., Butterfield, L. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.0500 · Cited by 141
Kast, W. M., Bronkhorst, A. M., de Waal, L. P., & Melief, C. J. M. (1986) · The Journal of Experimental Medicine · doi:10.1084/jem.164.3.723 · Cited by 140
Self-citationTherapeutic vaccination against human papilloma virus induced malignancies
van der Burg, S. H., & Melief, C. J. M. (2011) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.12.010 · Cited by 139
Self-citationKirkwood, J. M., Lee, S., Moschos, S. J., Albertini, M. R., Michalak, J. C., Sander, C., Whiteside, T. L., Butterfield, L. H., & Weiner, L. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1231 · Cited by 138
Speiser, D. E., Baumgaertner, P., Voelter, V., Devêvre, E., Barbey, C., Rufer, N., & Romero, P. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800080105 · Cited by 137
Complexity and challenges in defining myeloid-derived suppressor cells
Damuzzo, V., Pinton, L., Desantis, G., Solito, S., Marigo, I., Bronte, V., & Mandruzzato, S. (2014) · Cytometry Part B Clinical Cytometry · doi:10.1002/cytob.21206 · Cited by 136
DUX4 Suppresses MHC Class I to Promote Cancer Immune Evasion and Resistance to Checkpoint Blockade
Chew, G.-L., Campbell, A. E., Neef, E. D., Sutliff, N. A., Shadle, S. C., Tapscott, S. J., & Bradley, R. K. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.06.011 · Cited by 135
Targeting T cell metabolism in the tumor microenvironment: an anti‐cancer therapeutic strategy
Yin, Z., Bai, L., Li, W., Zeng, T., Tian, H., & Cui, J. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1409-3 · Cited by 133
Fu, J. L., Malm, I., Kadayakkara, D. K. K., Levitsky, H., Pardoll, D. M., & Kim, Y. J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2685 · Cited by 133
Taylor, G. S., Haigh, T. A., Gudgeon, N. H., Phelps, R. J., Lee, S. P., Steven, N. M., & Rickinson, A. B. (2003) · Journal of Virology · doi:10.1128/jvi.78.2.768-778.2004 · Cited by 132
Engelhard, V. H., Bullock, T. N. J., Colella, T. A., Sheasley-O’Neill, S. L., & Mullins, D. W. (2002) · Immunological Reviews · doi:10.1034/j.1600-065x.2002.18812.x · Cited by 128
Suehiro, Y., Hasegawa, A., Iino, T., Sasada, A., Watanabe, N., Matsuoka, M., Takamori, A., Tanosaki, R., Utsunomiya, A., Choi, I., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13302 · Cited by 125
Westdorp, H., Creemers, J. H. A., van Oort, I. M., Schreibelt, G., Gorris, M. A. J., Mehra, N., Simons, M., de Goede, A. L., van Rossum, M. M., Croockewit, A. J., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0787-6 · Cited by 124
van Dongen, M., Savage, N. D. L., Jordanova, E. S., Bruijn, I. H. B., Walburg, K. V., Ottenhoff, T. H. M., Hogendoorn, P. C. W., van der Burg, S. H., Gelderblom, H. A. J., & van Hall, T. (2009) · International Journal of Cancer · doi:10.1002/ijc.25113 · Cited by 123
Tumor vaccination using messenger RNA: prospects of a future therapy
Kreiter, S., Diken, M., Selmi, A., Türeci, Ö., & Şahin, U. (2011) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.03.007 · Cited by 122
Salazar, A. Μ., Erlich, R. B., Mark, A. S., Bhardwaj, N., & Herberman, R. B. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0024 · Cited by 122
Xu, D.-Z., Zhao, K., Guo, L., Chen, X., Wang, H., Zhang, J., Xie, Q., Ren, H., Wang, W.-X., Li, L., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002565 · Cited by 120
Choi, Y. J., Hur, S. Y., Kim, T. J., Hong, S. R., Lee, J. K., Cho, C., Park, K. S., Woo, J. W., Sung, Y. C., Suh, Y. S., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1513 · Cited by 120
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A. K., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., et al. (2017) · eScholarship (California Digital Library) · Cited by 120
Liu, Y., Yu, Y., Yang, S., Zeng, B., Zhang, Z., Jiao, G., Zhang, Y., Cai, L., & Yang, R. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0591-5 · Cited by 117
Hill, H. C., Conway, T. F., Sabel, M. S., Jong, Y. S., Mathiowitz, E., Bankert, R. B., & Egilmez, N. K. (2002) · PubMed · Cited by 117
Tumor‐specific CD 4+ T cells maintain effector and memory tumor‐specific CD 8+ T cells
Church, S., Jensen, S. M., Antony, P. A., Restifo, N. P., & Fox, B. A. (2013) · European Journal of Immunology · doi:10.1002/eji.201343718 · Cited by 115
van der Maaden, K., Heuts, J., Camps, M. G. M., Pontier, M., van Scheltinga, A. G. T. T., Jiskoot, W., OSSENDORP, F. A., & Bouwstra, J. A. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.11.035 · Cited by 115
Self-citationKriegsman, B. A., Vangala, P., Chen, B. J., Meraner, P., Brass, A. L., Garber, M., & Rock, K. L. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1900475 · Cited by 114
Mittendorf, E. A., Ardavanis, A. S., Symanowski, J. T., Murray, J. L., Shumway, N. M., Litton, J. K., Hale, D. F., Perez, S. A., Anastasopoulou, E. A., Pistamaltzian, N. F., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw150 · Cited by 113
Ito, F., Li, Q., Shreiner, A. B., Okuyama, R., Jure‐Kunkel, M., Teitz‐Tennenbaum, S., & Chang, A. E. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0590 · Cited by 111
Sevko, A., Sade-Feldman, M., Kanterman, J., Michels, T., Falk, C. S., Umansky, L., Ramacher, M., Kato, M., Schadendorf, D., Baniyash, M., et al. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.444 · Cited by 111
Akahori, Y., Wang, L., Yoneyama, M., Seo, N., Okumura, S., Miyahara, Y., Amaishi, Y., Okamoto, S., Mineno, J., Ikeda, H., et al. (2018) · Blood · doi:10.1182/blood-2017-08-802926 · Cited by 110
Vaccine-Induced Effector-Memory CD8+ T Cell Responses Predict Therapeutic Efficacy against Tumors
van Duikeren, S., Fransen, M. F., Redeker, A., Wieles, B., Platenburg, G. J., Krebber, W.-J., OSSENDORP, F. A., Melief, C. J. M., & Arens, R. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201540 · Cited by 107
Self-citationIn Situ Vaccination for the Treatment of Cancer
Hammerich, L., Bhardwaj, N., Kohrt, H. E. K., & Brody, J. (2016) · Immunotherapy · doi:10.2217/imt.15.120 · Cited by 105
Yazdi, M. T., van Riet, S., van Schadewijk, A. M., Fiocco, M. F., van Hall, T., Taube, C., Hiemstra, P. S., & van der Burg, S. H. (2015) · Oncotarget · doi:10.18632/oncotarget.6506 · Cited by 105
The evolving landscape of ‘next-generation’ immune checkpoint inhibitors: A review
Mazzarella, L., Duso, B. A., Trapani, D., Belli, C., D’Amico, P., Ferraro, E., Viale, G., & Curigliano, G. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.04.035 · Cited by 105
He, L.-Z., Prostak, N., Thomas, L. J., Vitale, L. A., Weidlick, J., Crocker, A., Pilsmaker, C. D., Round, S. M., Tutt, A., Glennie, M. J., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300409 · Cited by 104
Efficient Induction of Antitumor Immunity by Synthetic Toll-like Receptor Ligand–Peptide Conjugates
Zom, G. G., Khan, S., Britten, C. M., Sommandas, V., Camps, M. G. M., Loof, N. M., Budden, C. F., Meeuwenoord, N. J., Filippov, D. V., van der Marel, G. A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0223 · Cited by 104
Self-citationChapuis, A. G., Afanasiev, O. K., Iyer, J. G., Paulson, K. G., Parvathaneni, U., Hwang, J. H., Lai, I. P., Roberts, I. M., Sloan, H. L., Bhatia, S., et al. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0087 · Cited by 104
Bhatia, S., Longino, N. V., Miller, N. J., Kulikauskas, R. M., Iyer, J. G., Ibrani, D., Blom, A., Byrd, D. R., Parvathaneni, U., Twitty, C., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0972 · Cited by 103
Huang, L., Malu, S., McKenzie, J. A., Andrews, M. C., Talukder, A. H., Tieu, T., Karpinets, T., Haymaker, C., Forget, M.-A., Williams, L. J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2483 · Cited by 102
Asahara, S., Takeda, K., Yamao, K., Maguchi, H., & Yamaue, H. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-291 · Cited by 102
Grabowska, A. K., & Riemer, A. B. (2012) · The Open Virology Journal · doi:10.2174/1874357901206010249 · Cited by 101
Melssen, M. M., Petroni, G. R., Chianese‐Bullock, K. A., Wages, N. A., Grosh, W. W., Varhegyi, N., Smolkin, M. E., Smith, K. T., Galeassi, N. V., Deacon, D. H., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0625-x · Cited by 101
Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer
Wada, S., Jackson, C. M., Yoshimura, K., Yen, H., Getnet, D., Harris, T. J., Goldberg, M. V., Bruno, T. C., Grosso, J. F., Durham, N. M., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-89 · Cited by 99
van der Sluis, T. C., van Duikeren, S., Huppelschoten, S., Jordanova, E. S., Nejad, E. B., Sloots, A., Boon, L., Smit, V. T. H. B. M., Welters, M. J. P., OSSENDORP, F. A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2142 · Cited by 97
Self-citationGreaney, S. K., Algazi, A. P., Tsai, K. K., Takamura, K. T., Chen, L., Twitty, C., Zhang, L., Paciorek, A. T., Pierce, R. H., Le, M. H., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0359 · Cited by 97
Zhang, H., Hong, H. Y., Li, D., Ma, S., Di, Y., Stoten, A., Haig, N. A., di Gleria, K., Yu, Z., Xu, X., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m809456200 · Cited by 96
Oh, J., Barve, M. A., Matthews, C. M., Koon, E. C., Heffernan, T. P., Fine, B. A., Grosen, E. A., Bergman, M. K., Fleming, E. L., DeMars, L. R., et al. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.09.018 · Cited by 96
Twelve-year survival and immune correlates in dendritic cell–vaccinated melanoma patients
Groß, S., Erdmann, M., Haendle, I., Voland, S., Berger, T. G., Schultz, E. S., Strasser, E. F., Dankerl, P., Janka, R., Schliep, S., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.91438 · Cited by 96
Hazama, S., Nakamura, Y., Takenouchi, H., Suzuki, N., Tsunedomi, R., Inoue, Y., Tokuhisa, Y., Iizuka, N., Yoshino, S., Takeda, K., et al. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-63 · Cited by 94
Regulation of the IL-10-driven macrophage phenotype under incoherent stimuli
Chuang, Y., Hung, M. E., Cangelose, B. K., & Leonard, J. N. (2016) · Innate Immunity · doi:10.1177/1753425916668243 · Cited by 94
Intrinsic Resistance to Immune Checkpoint Blockade in a Mismatch Repair–Deficient Colorectal Cancer
Gurjao, C., Liu, D., Hofree, M., AlDubayan, S. H., Wakiro, I., Su, M.-J., Felt, K. D., Gjini, E., Brais, L. K., Rotem, A., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0683 · Cited by 94
Yoshimura, K., Minami, T., Nozawa, M., Kimura, T., Egawa, S., Fujimoto, H., Yamada, A., Itoh, K., & Uemura, H. (2016) · European Urology · doi:10.1016/j.eururo.2015.12.050 · Cited by 92
Engelhard, V. H., Obeng, R. C., Cummings, K. L., Petroni, G. R., Ambakhutwala, A. L., Chianese‐Bullock, K. A., Smith, K. T., Lulu, A. M., Varhegyi, N., Smolkin, M. E., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000262 · Cited by 92
Cuadros, C., Dominguez, A. L., Lollini, P., Croft, M., Mittler, R. S., Borgström, P., & Lustgarten, J. (2005) · International Journal of Cancer · doi:10.1002/ijc.21098 · Cited by 91
Fibroblastic FAP promotes intrahepatic cholangiocarcinoma growth via MDSCs recruitment
Lin, Y., Li, B., Yang, X., Cai, Q., Liu, W., Tian, M., Luo, H., Yin, W., Song, Y. Y., Shi, Y., et al. (2019) · Neoplasia · doi:10.1016/j.neo.2019.10.005 · Cited by 91
Hazama, S., Nakamura, Y., Tanaka, H., Hirakawa, K., TAHARA, K., Shimizu, R., Ozasa, H., Etoh, R., Sugiura, F., Okuno, K., et al. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-108 · Cited by 87
Tio, D., van der Woude, J., Prinsen, C. A. C., Jansma, E. P., Hoekzema, R., & van Montfrans, C. (2016) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14085 · Cited by 87
TLR Ligand–Peptide Conjugate Vaccines
Zom, G. G., Khan, S., Filippov, D. V., & OSSENDORP, F. A. (2012) · Advances in immunology · doi:10.1016/b978-0-12-396548-6.00007-x · Cited by 85
Self-citationDijkgraaf, E. M., Santegoets, S. J. A. M., Reyners, A. K. L., Goedemans, R., Nijman, H. W., van Poelgeest, M. I. E., van Erkel, A. R., Smit, V. T. H. B. M., Daemen, T., van der Hoeven, J. J. M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4772 · Cited by 84
Self-citationPotentiation of a p53‐SLP vaccine by cyclophosphamide in ovarian cancer: A single‐arm phase II study
Vermeij, R., Leffers, N., Hoogeboom, B., Hamming, I. L. E., Wolf, R., Reyners, A. K. L., Molmans, B. H. W., Hollema, H., Bart, J., Drijfhout, J. W., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27388 · Cited by 84
Self-citationvan der Sluis, T. C., Sluijter, M., van Duikeren, S., West, B. L., Melief, C. J. M., Arens, R., van der Burg, S. H., & van Hall, T. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0052 · Cited by 84
Self-citationCabrera, T., Lara, E., Romero, J. M., Maleno, I., Real, L. M., Ruiz‐Cabello, F., Valero, P. M., Camacho, F. M., & Garrido, F. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0226-7 · Cited by 83
Rettig, L., Seidenberg, S., Parvanova, I., Samaras, P., Knuth, A., & Pascolo, S. (2011) · International Journal of Cancer · doi:10.1002/ijc.25756 · Cited by 83
Pedersen, S. R., Sørensen, M. R., Buus, S., Christensen, J. P., & Thomsen, A. R. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300555 · Cited by 83
Wang, Q., Shashikant, C. S., Jensen, M., Altman, N., & Girirajan, S. (2017) · Scientific Reports · doi:10.1038/s41598-017-01005-x · Cited by 83
T Cell Help Amplifies Innate Signals in CD8+ DCs for Optimal CD8+ T Cell Priming
Greyer, M., Whitney, P. G., Stock, A. T., Davey, G. M., Tebartz, C., Bachem, A., Mintern, J. D., Strugnell, R. A., Turner, S. J., Gebhardt, T., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.058 · Cited by 80
Pavlick, A. C., Blazquez, A. B., Meseck, M. L., Lattanzi, M. W., Ott, P. A., Marron, T. U., Holman, R. M., Mandeli, J., Salazar, A. Μ., McClain, C. B., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0545 · Cited by 80
Metabolic Consequences of T-cell Costimulation in Anticancer Immunity
Teijeira, Á., Garasa, S., Etxeberría, I., Gato, M., Melero, I., & Delgoffe, G. M. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0115 · Cited by 78
Sharabi, A. B., Tran, P. T., Lim, M. K., Drake, C. G., & DeWeese, T. L. (2015) · PubMed · Cited by 77
Verdegaal, E. M. E., Visser, M., Ramwadhdoebé, T. H., van der Minne, C. E., van Steijn, J. A. Q. M. J., Kapiteijn, E., Haanen, J. B. A. G., van der Burg, S. H., Nortier, J. W. R., & Osanto, S. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1004-8 · Cited by 77
Tsuji, T., Sabbatini, P. J., Jungbluth, A. A., Ritter, E., Pan, L. S., Ritter, G., Ferran, L. J., Spriggs, D. R., Salazar, A. Μ., & Gnjatic, S. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0089 · Cited by 77
Cho, H. I., Barrios, K., Lee, Y.-R., Linowski, A. K., & Celis, E. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1382-6 · Cited by 76
Wilgenhof, S., Corthals, J., Nuffel, A. M. T. V., Benteyn, D., Heirman, C., Bonehill, A., Thielemans, K., & Neyns, B. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1642-8 · Cited by 76
Thoreau, M., Penny, H. L., Tan, K. W., Régnier, F., Weiss, J. M., Lee, B. T. K., Johannes, L., Dransart, E., Bon, A. L., Abastado, J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4940 · Cited by 74
Tumour‐induced immune suppression: role of inflammatory mediators released by myelomonocytic cells
Mao, Y., Poschke, I. C., & Kiessling, R. W. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12229 · Cited by 74
Kotsakis, A. P., Papadimitraki, E., Vetsika, E., Aggouraki, D., Dermitzaki, E. K., Hatzidaki, D., Kentepozidis, N. K., Mavroudis, D., & Georgoulias, V. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.07.018 · Cited by 74
Mkrtichyan, M., Chong, N., Eid, R. A., Wallecha, A., Singh, R., Rothman, J., & Khleif, S. N. (2013) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-1-15 · Cited by 74
Bailur, J. K., Gueckel, B., Derhovanessian, E., & Pawelec, G. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0541-z · Cited by 71
Sater, H. A., Marté, J. L., Donahue, R. N., Walter-Rodriguez, B., Heery, C. R., Steinberg, S. M., Cordes, L. M., Chun, G., Karzai, F. H., Bilušić, M., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000655 · Cited by 69
Immunopathogenesis of lymphoma: Focus on CCR4
Ishida, T., & Ueda, R. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01767.x · Cited by 67
Liu, S., Peng, N., Xie, J., Qian, H., Zhang, M., Zhang, Y., Xia, Z., Xu, G., Zhao, F., Wang, Q., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.11.035 · Cited by 67
Baumgaertner, P., Nunes, C. C., Cachot, A., Hajjami, H. M.-E., Cagnon, L., Braun, M., Derré, L., Rivals, J. P., Rimoldi, D., Gnjatic, S., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1216290 · Cited by 67
ADXS-HPV: A therapeuticListeriavaccination targeting cervical cancers expressing the HPV E7 antigen
Cory, L. A., & Chu, C. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.34378 · Cited by 66
Provencio-Pulla, M., Nadal-Alforja, E., Cobo, M., Insa, A., Rivas, M. C., Majem, M., Rodríguez‐Abreu, D., López-Vivanco, G., Dómine, M., del Barco, E., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.8521 · Cited by 66
O’Hara, M. H., O'Reilly, E. M., Mick, R., Varadhachary, G. R., Wainberg, Z. A., Ko, A. H., Fisher, G. A., Rahma, O. E., Lyman, J. P., Cabanski, C. R., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-ct004 · Cited by 66
Weide, B., Eigentler, T., Pflugfelder, A., Leiter, U., Meier, F. E., Bauer, J. M., Schmidt, D., Radny, P., Pföhler, C., & Garbe, C. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0957-3 · Cited by 64
Miyauchi, S., Sanders, P. D., Guram, K., Kim, S. S., Paolini, F., Venuti, A., Cohen, E. E. W., Gutkind, J. S., Califano, J. A., & Sharabi, A. B. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-1771 · Cited by 64
van den Bulk, J., Verdegaal, E. M. E., Ruano, D., Ijsselsteijn, M. E., Visser, M., van der Breggen, R., Duhen, T., van der Ploeg, M., de Vries, N. L., Oosting, J., et al. (2019) · Genome Medicine · doi:10.1186/s13073-019-0697-8 · Cited by 63
Self-citationTargeting the tumor mutanome for personalized vaccination therapy
Kreiter, S., Castle, J. C., Türeci, Ö., & Şahin, U. (2012) · OncoImmunology · doi:10.4161/onci.19727 · Cited by 62
Pathogen-Driven Cancers and Emerging Immune Therapeutic Strategies
Vandeven, N. A., & Nghiem, P. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0179 · Cited by 62
An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma
Reardon, D. A., Wucherpfennig, K. W., Freeman, G. J., Wu, C. J., Chiocca, E. A., Wen, P. Y., Curry, W. T., Mitchell, D. A., Fecci, P. E., Sampson, J. H., et al. (2013) · Expert Review of Vaccines · doi:10.1586/erv.13.41 · Cited by 62
Aarntzen, E. H. J. G., Bol, K. F., Schreibelt, G., Jacobs, J. F. M., Lesterhuis, W. J., van Rossum, M. M., Adema, G. J., Figdor, C. G., Punt, C. J. A., & de Vries, I. J. M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2479 · Cited by 61
Bos, R., van Duikeren, S., van Hall, T., Kaaijk, P., Taubert, R., Kyewski, B., Klein, L., Melief, C. J. M., & Offringa, R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0666 · Cited by 60
Self-citationStrategies to Eliminate HBV Infection
Kapoor, R., & Kottilil, S. (2014) · Future Virology · doi:10.2217/fvl.14.36 · Cited by 60
Bos, R., van Duikeren, S., Morreau, H. M., Franken, K. L. M. C., Schumacher, T. N., Haanen, J. B. A. G., van der Burg, S. H., Melief, C. J. M., & Offringa, R. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1864 · Cited by 60
Self-citationMatoba, T., Imai, M., Ohkura, N., Kawakita, D., Ijichi, K., Toyama, T., Morita, A., Murakami, S., Sakaguchi, S., & Yamazaki, S. (2018) · International Journal of Cancer · doi:10.1002/ijc.32024 · Cited by 59
Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer
Arens, R., van Hall, T., van der Burg, S. H., OSSENDORP, F. A., & Melief, C. J. M. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.04.008 · Cited by 58
Self-citationNoguchi, M., Matsumoto, K., Uemura, H., Arai, G., Eto, M., Naito, S., Οhyama, C., Nasu, Y., Tanaka, M., Moriya, F., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1265 · Cited by 57
Ishikawa, H., Imano, M., Shiraishi, O., Yasuda, A., Peng, Y., Shinkai, M., Yasuda, T., Imamoto, H., & Shiozaki, H. (2013) · Gastric Cancer · doi:10.1007/s10120-013-0258-6 · Cited by 55
Carretero, R., Cabrera, T., Gil-Julio, H., Sáenz-López, P., Maleno, I., Aptsiauri, N., Cozar, J. M., & Garrido, F. (2010) · International Journal of Cancer · doi:10.1002/ijc.25733 · Cited by 55
Heidegger, S. M., Kreppel, D., Bscheider, M., Stritzke, F., Nedelko, T., Wintges, A., Bek, S., Fischer, J. C., Graalmann, T., Kalinke, U., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.02.056 · Cited by 55
Immune control and failure in HCV infection—tipping the balance
Dustin, L. B., Cashman, S. B., & Laidlaw, S. M. (2014) · Journal of Leukocyte Biology · doi:10.1189/jlb.4ri0214-126r · Cited by 53
Suzuki, S., Sakata, J., Utsumi, F., Sekiya, R., Kajiyama, H., Shibata, K., Kikkawa, F., & Nakatsura, T. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1238542 · Cited by 52
Welters, M. J. P., Bijker, M. S., van den Eeden, S. J. F., Franken, K. L. M. C., Melief, C. J. M., Offringa, R., & van der Burg, S. H. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.10.049 · Cited by 51
Self-citationChandran, S. S., Paria, B. C., Srivastava, A. K., Rothermel, L. D., Stephens, D. J., Dudley, M. E., Somerville, R. P. T., Wunderlich, J. R., Sherry, R. M., Yang, J. C.-H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2208 · Cited by 51
Hansen, G. L., Gaudernack, G., Brunsvig, P. F., Cvancarova, M., & Kyte, J. A. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1766-5 · Cited by 50
Regulation of Chemokine Expression in the Tumor Microenvironment
Gorbachev, A. V., & Fairchild, R. L. (2014) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2014010062 · Cited by 50
Pinto, S., Sommermeyer, D., Michel, C., Wilde, S., Schendel, D. J., Uckert, W., Blankenstein, T. J. F., & Kyewski, B. (2014) · European Journal of Immunology · doi:10.1002/eji.201444499 · Cited by 49
Immunologic treatments for precancerous lesions and uterine cervical cancer
Vici, P., Mariani, L., Pizzuti, L., Sergi, D., Lauro, L. D., Vizza, E., Tomao, F., Tomao, S., Cavallotti, C., Paolini, F., et al. (2014) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-33-29 · Cited by 49
Morisaki, T., Hikichi, T., Onishi, H., Morisaki, T., Kubo, M., Hirano, T., Yoshimura, S., Kiyotani, K., & Nakamura, Y. (2020) · Immunological Investigations · doi:10.1080/08820139.2020.1778721 · Cited by 49
Santegoets, S. J., Duurland, C. L., Jordanova, E. S., van Ham, J. J., Ehsan, I., van Egmond, S. L., Welters, M. J. P., & van der Burg, S. H. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0497-0 · Cited by 48
Self-citationRadiotherapy Cooperates with IL15 to Induce Antitumor Immune Responses
Pilones, K. A., Charpentier, M., García-Martínez, E., Daviaud, C., Kraynak, J., Aryankalayil, J. B., Formenti, S. C., & Demaria, S. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0338 · Cited by 48
Sundarasetty, B. S., Chan, L., Darling, D., Giunti, G., Farzaneh, F., Schenck, F., Naundorf, S., Kuehlcke, K., Ruggiero, E., Schmidt, M., et al. (2015) · Gene Therapy · doi:10.1038/gt.2015.43 · Cited by 46
Borch, T. H., Engell-Noerregaard, L., Iversen, T. Z., Ellebæk, E., Met, Ö., Hansen, M., Andersen, M. H., Straten, P. T., & Svane, I. M. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1207842 · Cited by 46
Hoyer, S., Prommersberger, S., Pfeiffer, I. A., Schuler‐Thurner, B., Schuler, G., Dörrie, J., & Schaft, N. (2014) · European Journal of Immunology · doi:10.1002/eji.201444477 · Cited by 45
Santegoets, S. J. A. M., de Groot, A. F., Dijkgraaf, E. M., Simões, A. M. C., van der Noord, V. E., van Ham, J. J., Welters, M. J. P., Kroep, J. R., & van der Burg, S. H. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1465166 · Cited by 45
Tsuji, K., Hamada, T., Uenaka, A., Wada, H., Sato, E., Isobe, M., Asagoe, K., Yamasaki, O., Shiku, H., Ritter, G., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0478-5 · Cited by 44
Dendritic/Tumor Fusion Cells as Cancer Vaccines
Avigan, D., Rosenblatt, J. M., & Kufe, D. W. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.02.003 · Cited by 42
Quakkelaar, E. D., & Melief, C. J. M. (2012) · Advances in immunology · doi:10.1016/b978-0-12-396548-6.00004-4 · Cited by 41
Self-citationDu, S., & Barcellos‐Hoff, M. H. (2013) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2013.05.001 · Cited by 41
Milagre, C. S., Gopinathan, G., Everitt, G. L. A., Thompson, R. G., Kulbe, H., Zhong, H., Hollingsworth, R. E., Grose, R. P., Bowtell, D. D. L., Hochhauser, D., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1801 · Cited by 41
Gomez, B. P., He, L., Tsai, Y. C., Wu, T. ‐., Viscidi, R. P., & Hung, C. (2013) · Cell & Bioscience · doi:10.1186/2045-3701-3-29 · Cited by 41
Frank, M. J., Khodadoust, M. S., Czerwinski, D. K., Haabeth, O. A. W., Chu, M. P., Miklos, D. B., Advani, R. H., Alizadeh, A. A., Gupta, N. K., Maeda, L. S., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20191712 · Cited by 41
Complete molecular response in CML after p210 BCR–ABL1-derived peptide vaccination
Bocchia, M., Defina, M., Aprile, L., Ippoliti, M., Crupi, R., Rondoni, M., Gozzetti, A., & Lauria, F. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.141 · Cited by 39
Tumor lysate-loaded biodegradable microparticles as cancer vaccines
Joshi, V. B., Geary, S. M., Gross, B., Wongrakpanich, A., Norian, L. A., & Salem, A. K. (2013) · Expert Review of Vaccines · doi:10.1586/14760584.2014.851606 · Cited by 39
Lemos, H. D. P., Huang, L., McGaha, T. L., & Mellor, A. L. (2014) · European Journal of Immunology · doi:10.1002/eji.201344407 · Cited by 38
Camisaschi, C., Filipazzi, P., Tazzari, M., Casati, C., Beretta, V., Pilla, L., Patuzzo, R., Maurichi, A., Cova, A., Maio, M., et al. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1397-7 · Cited by 38
Ohue, Y., Eikawa, S., Okazaki, N., Mizote, Y., Isobe, M., Uenaka, A., Fukuda, M., Old, L. J., Oka, M., & Nakayama, E. (2011) · International Journal of Cancer · doi:10.1002/ijc.27359 · Cited by 37
Survivin and PSMA Loaded Dendritic Cell Vaccine for the Treatment of Prostate Cancer
Xi, H., Wang, G., Fu, B., Liu, W., & Yu, L. J. (2015) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b14-00518 · Cited by 36
Immune adjuvants as critical guides directing immunity triggered by therapeutic cancer vaccines
Schijns, V. E. C. J., Tartour, É., Michálek, J., Stathopoulos, A., Dobrovolskienė, N., & Strioga, M. M. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2013.09.008 · Cited by 35
Dehlin, M., Andersson, S. E. M., Erlandsson, M. C., Brisslert, M., & Bokarewa, M. I. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.1110640 · Cited by 33
Lysén, A., Braathen, R., Gudjonsson, A., Tesfaye, D. Y., Bogen, B., & Fossum, E. (2019) · Scientific Reports · doi:10.1038/s41598-018-38080-7 · Cited by 33
Pas, T. M. D., Giovannini, M., Rescigno, M., Catania, C., Toffalorio, F., Spitaleri, G., Delmonte, A., Barberis, M. C. P., Spaggiari, L., Solli, P., et al. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.12.005 · Cited by 32
Human Leukocyte Antigen (HLA) Typing by DNA Sequencing
Lázaro, A. M. P., Tu, B., Yang, R., Xiao, Y., Kariyawasam, K., Ng, J., & Hurley, C. K. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-493-7_9 · Cited by 31
Mechanisms of Peptide Vaccination in Mouse Models
van Hall, T., & van der Burg, S. H. (2012) · Advances in immunology · doi:10.1016/b978-0-12-396548-6.00003-2 · Cited by 30
Histochemical demonstration of hydroxysteroid dehydrogenase activity in the mature canine ovary
Fowler, E. H., & Feldman, M. K. (1970) · General and Comparative Endocrinology · doi:10.1016/0016-6480(70)90032-8 · Cited by 29
van Esch, E. M. G., van Poelgeest, M. I. E., Kouwenberg, S., Osse, E. M., Trimbos, J. B., Fleuren, G. J., Jordanova, E. S., & van der Burg, S. H. (2014) · International Journal of Cancer · doi:10.1002/ijc.29174 · Cited by 28
Prado, F. B., Rossi, A. C., Freire, A. R., Groppo, F. C., de Moraes, M., & Cária, P. H. F. (2012) · Dentomaxillofacial Radiology · doi:10.1259/dmfr/22419253 · Cited by 26
Palettes of Vaccines and Immunostimulatory Monoclonal Antibodies for Combination
Melero, I., Martínez‐Forero, I., Dubrot, J., Suárez, N., Palazón, A., & Chen, L. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2931 · Cited by 26
Targeting STING pathways for the treatment of cancer
Gravekamp, C., & Chandra, D. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.988463 · Cited by 22
Cancer vaccines targeting carcinoembryonic antigen: state-of-the-art and future promise
Gameiro, S. R., Jammeh, M. L., & Hodge, J. W. (2013) · Expert Review of Vaccines · doi:10.1586/erv.13.40 · Cited by 22
Ochsenreither, S., Fusi, A., Geikowski, A., Stather, D., Busse, A., Stroux, A., Letsch, A., & Keilholz, U. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1099-y · Cited by 22
He, Y., Yuan, H., & Mizejewski, G. J. (2014) · Immunotherapy · doi:10.2217/imt.14.46 · Cited by 21
van den Boorn, J. G., Barchet, W., & Hartmann, G. (2012) · Advances in immunology · doi:10.1016/b978-0-12-396548-6.00001-9 · Cited by 21
Øynebråten, I., Hinkula, J., Fredriksen, A. B., & Bogen, B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104814 · Cited by 19
Local and systemic XAGE-1b-specific immunity in patients with lung adenocarcinoma
Yazdi, M. T., Loof, N. M., Franken, K. L. M. C., Taube, C., Oostendorp, J., Hiemstra, P. S., Welters, M. J. P., & van der Burg, S. H. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1716-2 · Cited by 18
Abdulrahman, Z., de Miranda, N. F. C. C., Hellebrekers, B. W. J., van Steenwijk, P. J. D. V., van Esch, E. M. G., van der Burg, S. H., & van Poelgeest, M. I. E. (2020) · International Journal of Cancer · doi:10.1002/ijc.33168 · Cited by 18
van Elsas, M. J., Kleinovink, J. W., Moerland, M., Feiss, G. L., Beyrend, G., Arens, R., Mei, H., Nibbering, P. H., Jirka, S. M. G., van Hall, T., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000877 · Cited by 15
Self-citationHuman Cytomegalovirus Antigens in Malignant Gliomas as Targets for Adoptive Cellular Therapy
Landi, D. B., Hegde, M. G., & Ahmed, N. M. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00338 · Cited by 14
Cited by
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
Delivery technologies for cancer immunotherapy
Riley, R. S., June, C. H., Langer, R., & Mitchell, M. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0006-z · Cited by 2,607
CD4+ T cell help in cancer immunology and immunotherapy
Borst, J., Ahrends, T., Bąbała, N., Melief, C. J. M., & Kastenmüller, W. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0044-0 · Cited by 1,585
Self-citationSaxena, M., van der Burg, S. H., Melief, C. J. M., & Bhardwaj, N. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00346-0 · Cited by 1,581
Self-citationCancer immunotherapy: harnessing the immune system to battle cancer
Yang, Y. (2015) · Journal of Clinical Investigation · doi:10.1172/jci83871 · Cited by 1,359
Metadata
- Authors
- Melief, C. J. M., van Hall, T., Arens, R., Ossendorp, F., & van der Burg, S. H.
- Venue
- Journal of Clinical Investigation
- Published
- 2015-07-27
- Volume
- 125
- Issue
- 9
- Pages
- 3401-3412
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1938515409
- Cited by
- 1,164
- References
- 377
- FWCI
- 22.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.